Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensCell Lines for BBB Modeling
- Immortalized Cells for BBB ModelingPrimary Cells for BBB ModelingStem Cells for BBB ModelingProteins & Peptides for Stroke ResearchOnline Inquiry
Human KLC1 ELISA Kit (AC3082)
Cat.#: ASET-1671
Specifications
Description Human KLC1 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human KLC1 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 2.44 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 75-1200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1739 Human Repulsive Guidance Molecule A ELISA Kit (AC3150) Quantitative inquiry ASET-1705 Rat Galanin ELISA Kit (AC3116) Quantitative inquiry ASET-1512 Human P2Y1 ELISA Kit (AC2923) Quantitative inquiry ASET-2046 Human Activin B ELISA Kit (AC3457) Quantitative inquiry ASET-2535 Mouse Kappa Opioid Receptor ELISA Kit (AC3946) Quantitative inquiry ASET-2514 Human ABCA7 ELISA Kit (AC3925) Quantitative inquiry ASET-1338 Human FOXO1A ELISA Kit (AC2749) Quantitative inquiry ASET-1722 Human NDP ELISA Kit (AC3133) Quantitative inquiry ASET-2452 Rat Orexin A ELISA Kit (AC3863) Quantitative inquiry ASET-1343 Human Netrin 4 ELISA Kit (AC2754) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket